Biomed AI- Artificial Intelligence for Drug Discovery
Biomed AI, Inc. is a technology company built to transform the drug discovery and development process using Human Real World Evidence and artificial intelligence-driven computation.
The cost to develop a new drug is every expensive, exceeding $2.6 billion. It normally takes 15-20 years from drug screening, lab testing, animal studies, Phase 1, Phase 2 and Phase 3 clinical trials and the stringent FDA regulatory process. Recent advances in artificial intelligence (AI) may help to reverse this trend and accelerate and improve pharmaceutical research and development.
Biomed AI aims to fully integrate Human Real World Evidence (HRWE) data across the entire drug development and clinical trial life cycle, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates.
The company’s Biomed AI Platform™ applies the state-of-the-art CHAT-GPT-4 to transform data into valuable insights that may accelerate discoveries and enable Biomed Industries, Inc. to advance a robust pipeline of programs in neurodegenerative diseases.
Using training DNNs on transcriptional response data we can predict the pharmacological properties of small molecules (1) and biomarker development, (2) to the generation of novel chemistry.
One of medicinal chemistry related machine learning challenges is the selection of the representation of molecular structure to capture as many of the relevant chemical and biological features and come as close to reality as possible.
(Ref: Alex Zhavoronkov- Mol. Pharmaceutics 2018, 15, 10, 4311–4313)
The Biomed team has successfully demonstrated the application of AI in developing new drug therapeutics for the treatment of neurodegenerative diseases. We plan to deploy our AI technology to optimize the Phase 2 and Phase 3 clinical trials of our drug NA-831 for the treatment and prevention of Alzheimer’s disease.
